menu
    • menu
    [{"orgOrder":0,"company":"Saptalis pharm","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Saptalis pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Saptalis pharm \/ Saptalis","highestDevelopmentStatusID":"6","companyTruncated":"Saptalis pharm \/ Saptalis"},{"orgOrder":0,"company":"Saptalis pharm","sponsor":"Appili Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Saptalis pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Saptalis pharm \/ Saptalis pharm","highestDevelopmentStatusID":"12","companyTruncated":"Saptalis pharm \/ Saptalis pharm"}]

    Find Clinical Drug Pipeline Developments & Deals by Saptalis pharm

    Menu

    Saptalis pharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Saptalis pharm

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Saptalis pharm

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Appili Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension

                            Details : Likmez(metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organi...

                            Brand Name : Likmez

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 25, 2023

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Appili Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Saptalis pharm

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Saptalis pharm

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Appili Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals

                            Details : Under the terms of the amended agreement, Saptalis will assume responsibility for development and commercialization of ATI-1501 in Europe and Latin America (collectively, the “Expanded Territories”).

                            Brand Name : ATI-1501

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 08, 2022

                            Lead Product(s) : Metronidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Appili Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth